Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway

Table 1 Patients characteristics

Number	Diagnosis	Relapse or refractory	sample	Blast	Treatment
1	AML-M2	Relapse	PB	91.2%	MA, DCAG
2	AML-M2	Relapse	PB	87.5%	CAG, IA,
3	AML-M4	Relapse	PB	85.6%	DCAG, MA
4	AML-M5	refractory	PB	98.7%	DA, DCAG

Abbreviations: PB peripheral blood, MA mitoxantrone + cytarabine, DA doxorubicin +cytarabine, DCAG decitabine + aclacinomycin +cytarabine +granulocyte colony stimulating factor, CAG aclacinomycin + cytarabine + granulocyte-colony stimulating factor;

ISSN: 1756-9966